Ambien Cardiovascular Impact Long-Term: What the Evidence Actually Shows

What the labels record

In three placebo-controlled Ambien trials lasting 28 to 35 nights (152 patients on zolpidem up to 10 mg, 161 on placebo), palpitations were reported by 2% of zolpidem patients and chest pain by 1%; the label lists no placebo figure for either [1]. In trials of up to 10 nights, the label identifies drowsiness (2%), dizziness (1%) and diarrhea (1%) as the most common adverse reactions with statistically significant differences from placebo; headache was 7% on zolpidem versus 6% on placebo [1].

Ambien CR adds a blood-pressure line: in a 3-week trial of 12.5 mg (102 patients) versus placebo (110), increased blood pressure was reported by 1% versus 0% [2]. A 24-week trial of extended-release zolpidem taken 3 to 7 nights a week reported headache, anxiety and somnolence as the most frequent adverse events [5].

The mortality cohort

Kripke and colleagues' matched cohort, published in BMJ Open in 2012, drew records from a large integrated US health system: 10,529 patients prescribed hypnotics and 23,676 controls with none, matched on 12 comorbidity classes and adjusted for age, sex, smoking, body mass index, ethnicity, marital status, alcohol use and prior cancer. Mean follow-up was 2.5 years [3].

Hazard ratios for death rose with prescription volume: 3.60 (95% CI 2.92 to 4.44) at 0.4 to 18 doses per year, 4.43 (3.67 to 5.36) at 18 to 132, and 5.32 (4.50 to 6.30) above 132 [3]. The hypnotics studied included zolpidem along with benzodiazepines and other drugs. The outcomes reported in the abstract are all-cause death and incident cancer; it does not report heart attack, stroke or heart failure results [3].

What the label warns about

The Ambien label says to consider the risk of respiratory depression in patients with compromised respiratory function, and says opioids may add to that risk [1]. It also warns of CNS depression, next-day impairment and falls, especially in older patients [1]. The boxed warning covers complex sleep behaviors that can cause serious injury or death; an analysis of FDA adverse-event reports and medical literature through February 2018 identified 66 serious cases involving Z-drugs, including 20 deaths and 46 serious injuries [6].

The 2023 AGS Beers Criteria advise avoiding zolpidem in adults 65 and older (strong recommendation, moderate-quality evidence) because of delirium, falls, fractures and crashes with minimal sleep benefit [4]. For older adults, the Ambien label lists 5 mg for immediate-release tablets [1], while the Ambien CR label lists 6.25 mg for extended-release tablets [2].

The label indication is short-term, the label says treatment should be as short as possible, and insomnia persisting 7 to 10 days should be re-evaluated [1]; the American College of Physicians recommends CBT-I as the initial treatment for chronic insomnia [7].